As Sanofi (SNY) Market Valuation Rose, Holder Senzar Asset Management LLC Has Lowered by $8.02 Million Its Position

July 18, 2017 - By Nellie Frank

Senzar Asset Management Llc decreased its stake in Sanofi (SNY) by 13.97% based on its latest 2016Q4 regulatory filing with the SEC. Senzar Asset Management Llc sold 200,400 shares as the company’s stock rose 14.25% with the market. The hedge fund held 1.23M shares of the major pharmaceuticals company at the end of 2016Q4, valued at $49.91M, down from 1.43 million at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Sanofi for a number of months, seems to be less bullish one the $121.27B market cap company. The stock increased 0.04% or $0.02 on July 17, reaching $48.18. About shares traded. Sanofi SA (ADR) (NYSE:SNY) has risen 26.96% since July 18, 2016 and is uptrending. It has outperformed by 10.26% the S&P500.

Senzar Asset Management Llc, which manages about $442.00M and $377.08M US Long portfolio, upped its stake in Shire Plc (NASDAQ:SHPG) by 58,500 shares to 196,400 shares, valued at $33.46 million in 2016Q4, according to the filing. It also increased its holding in Express Scripts Hldg Co (NASDAQ:ESRX) by 149,301 shares in the quarter, for a total of 447,001 shares, and has risen its stake in Halozyme Therapeutics Inc (NASDAQ:HALO).

Analysts expect Sanofi SA (ADR) (NYSE:SNY) to report $0.78 EPS on August, 4.They anticipate $0.04 EPS change or 5.41 % from last quarter’s $0.74 EPS. SNY’s profit would be $1.96B giving it 15.44 P/E if the $0.78 EPS is correct. After having $0.76 EPS previously, Sanofi SA (ADR)’s analysts see 2.63 % EPS growth.

More recent Sanofi SA (ADR) (NYSE:SNY) news were published by: Investorplace.com which released: “3 Stocks to Watch on Monday: Tesla Inc (TSLA), Sanofi SA (ADR) (SNY) and …” on April 03, 2017. Also Investorplace.com published the news titled: “5 Reasons Why Sanofi SA (ADR) (SNY) is a Good Stock to Buy Now” on April 12, 2017. Investorplace.com‘s news article titled: “Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma” with publication date: December 09, 2016 was also an interesting one.

Sanofi SA (ADR) (NYSE:SNY) Ratings Coverage

Among 10 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Sanofi-aventis Sa has $56 highest and $50.0 lowest target. $53’s average target is 10.00% above currents $48.18 stock price. Sanofi-aventis Sa had 16 analyst reports since October 15, 2015 according to SRatingsIntel. Piper Jaffray initiated the stock with “Neutral” rating in Friday, September 23 report. The firm earned “Neutral” rating on Tuesday, September 13 by BNP Paribas. The firm has “Neutral” rating by JP Morgan given on Friday, April 21. As per Tuesday, May 3, the company rating was downgraded by HSBC. Barclays Capital upgraded the shares of SNY in report on Thursday, May 12 to “Overweight” rating. The stock of Sanofi SA (ADR) (NYSE:SNY) has “Neutral” rating given on Wednesday, April 12 by JP Morgan. Goldman Sachs initiated the shares of SNY in report on Monday, November 7 with “Neutral” rating. Berenberg upgraded the shares of SNY in report on Thursday, September 8 to “Buy” rating. The stock of Sanofi SA (ADR) (NYSE:SNY) earned “Reduce” rating by HSBC on Friday, April 7. BNP Paribas downgraded the stock to “Underperform” rating in Thursday, December 10 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.